GD
PDSB icon

Grandfield & Dodd’s PDS Biotechnology PDSB Stock Holding History

Grandfield & Dodd’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.81K Hold
10,000
– – ﹤0.01% 217
2026
Q1 		$6.05K Hold
10,000
– – ﹤0.01% 209
2025
Q4 		$7.7K Hold
10,000
– – ﹤0.01% 207
2025
Q3 		$10.1K Hold
10,000
– – ﹤0.01% 211
2025
Q2 		$13.3K Buy
+10,000
New +$13.6K ﹤0.01% 212

Other funds holding PDSB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Grandfield & Dodd's PDSB Position: Q2 2026 in Review

Grandfield & Dodd held its PDS Biotechnology (PDSB) position steady in Q2 2026 at 10,000 shares worth $8.81K. The position accounts for ﹤0.01% of the portfolio, ranked #217.

Grandfield & Dodd first reported a position in PDSB in Q2 2025 and has held it in 5 quarters since. The position peaked at $13.3K in Q2 2025. 52 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.

  • Grandfield & Dodd held 10,000 shares of PDS Biotechnology worth $8.81K as of Q2 2026.
  • Grandfield & Dodd left its PDS Biotechnology share count unchanged in Q2 2026.
  • PDS Biotechnology made up ﹤0.01% of Grandfield & Dodd's portfolio in Q2 2026, its #217 holding.
  • Grandfield & Dodd first reported a position in PDS Biotechnology in Q2 2025 and has held it in 5 quarters since.
  • Grandfield & Dodd's PDS Biotechnology position peaked at $13.3K in Q2 2025.
  • 52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.

Based on Grandfield & Dodd's 13F filing for Q2 2026, filed 7 Aug 2026.